German Version French Version


Chlordiazepoxide, 7-Chlor-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide
C16H14ClN3O, MW 299,75 g/mol

1,4-Benzodiazepine (long-working) T 1/2 10 to 15 hours, metabolites 50 to 90 hours

Trade Mark: Librium®, Radepur®, Multum® (numerous generica)


For the symptomatic treatment of acute and chronic tension, excitation and fear conditions (tranquilizer), as muscle relaxant for the therapy of epileptic accumulations, sleep disturbances and alcohol withdrawl syptoms.


Do not use during pregnancy, especially in the third trimester, or during breastfeeding. Chlordiazepoxide passes into breast milk. It may cause drowsiness.

Reciprocal effects

Chlordiazepoxide strengthens the effect of other muscle relaxants as well as from laughing gas and analgesics. The effect of Chlordiazepoxide is strengthened by alcohol. Cimetidine restrains the dismantling at the Cytochrome P450 and therefore extends the effect.

Adverse Effects

Chlordiazepoxide impairs reactivity and causes with income over a longer period a psychological and, in addition, physical dependence. When suddently set off withdrawal symptoms arise.


Therapeutic blood levels: 0.4 to 3 µg/ml. Metabolites: Oxazepam, Nordazepam, Desmethylchlordiazepoxide


Chlordiazepoxide was first synthesized in 1960 by L.H. Sternbach from Hoffmann LaRoche and marked under the label Librium®.

Custom Search




Last modification (M-D-Y): 02/08/2019 - IMPRINT - FAQ